NasdaqCM - Delayed Quote USD

Kazia Therapeutics Limited (KZIA)

1.5800

-0.1000

(-5.95%)

At close: January 10 at 4:00:00 PM EST

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 1,333,333 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing 100 ordinary shares of the Company, at a purchase price of $1.50 per ADS (or ADS equivalent in lieu thereof), in a registered direct offering. The

PR Newswire 20 hours ago

KZIA
-5.95%
Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?

Kazia Therapeutics Limited (NASDAQ:KZIA) stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with the FDA. In July 2024, the company reported topline results from the GBM-AGILE study in which newly diagnosed unmethylated patients with glioblastoma treated with paxalisib showed a clinically meaningful improvement in a prespecified secondary analysis for overall survival (OS) compared to standard

Benzinga 10 days ago

KZIA
-5.95%
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of glioblastoma (GBM) following its Type C clinical meeting with the United States Food and Drug Administration (FDA).

PR Newswire 10 days ago

KZIA
-5.95%
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development, announced that data from two abstracts will be presented at the San Antonio Breast Cancer Symposium highlighting the activity the Company's lead product candidate, paxalisib, for the potential treatment of immunotherapy-resistant triple negative breast cancer (TNBC) and HER2 positive metastatic breast cancer with active brain metastases.

PR Newswire 30 days ago

KZIA
-5.95%
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting with the Company in December 2024 to discuss the potential pathways to registration of Kazia's blood brain barrier penetrant PI3K/mTOR inhibitor, paxalisib, for the treatment of patients with newly diagnosed GBM.

PR Newswire 2 months ago

KZIA
-5.95%
Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics plans to modify the ratio of its American Depositary Shares (ADS) to improve its trading price on Nasdaq, with the new ratio set to take effect on October 28, 2024. This change aims to help the company meet Nasdaq’s minimum bid price requirement, but there is no guarantee it will succeed. The adjustment will not affect the number of underlying Ordinary Shares, and the company’s stock will continue to trade under the ticker symb

TipRanks 2 months ago

KZIA
-5.95%
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced the presentation of data from a Phase I study (NCT04192981) evaluating concurrent paxalisib and radiation therapy (RT) in patients for the treatment of solid tumor brain metastases (BM) or leptomeningeal metastases (LM) harboring PI3K pathway mutations at the American Society for Radiation Oncology 66th Annual Meeting (ASTRO 2024), which is taking place from September 29 - October 2, 2024, in Washi

PR Newswire 3 months ago

KZIA
-5.95%
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington.

PR Newswire 3 months ago

KZIA
-5.95%
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an agreement has been executed with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to obtain an exclusive license to certain intellectual property rights in relation to combination therapies consisting of PI3K inhibitor drugs, and one or more immunotherapy or PARP inhibitor drugs (PI3K combination).

PR Newswire 3 months ago

KZIA
-5.95%
7 Top Stocks Under $10: July 2024 Edition

While investing in the best blue chip stocks to anchor your portfolio is always a good idea, I am always looking to diversify. A good way to do that is to invest in lesser-known but quality stocks under $10. Lower-priced stocks have the advantage of being affordable so that you can buy more shares with less money. It’s much cheaper to buy 100 shares of a $5 stock than to buy the same number of shares of an equity that cost $100 or more, right? And these lower-priced stocks still can outperform t

InvestorPlace 5 months ago

SNGX

VVPR

KZIA
-5.95%
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?

Australian biotech company Kazia Therapeutics (NASDAQ:KZIA) stock rocked the market after reporting encouraging results from a Phase II/III trial for its glioblastoma brain cancer therapy Paxalisib. The positive results extended the life of patients by over three months compared to the current standard of care. Because the patients were a difficult-to-treat population, the results gave the oncology biotech developer cause to arrange a meeting with the Food & Drug Administration (FDA) to pursue a

InvestorPlace 5 months ago

KZIA
-5.95%
Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics

Biotechnology stock traders, listen up! Do you like to roll the dice and take your chances on promising drug developers? If so, then you’ll definitely want to add Kazia Therapeutics (NASDAQ:KZIA) to your watch list. I can’t guarantee any safety whatsoever, but Kazia Therapeutics stock offers excitement and the possibility of substantial profits. Or, Kazia Therapeutics might not secure full regulatory approval for its primary product, and the stock could go nowhere or just go to zero. Nearly any

InvestorPlace 5 months ago

KZIA
-5.95%
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Kazia (KZIA) surges after positive data from a phase II/III study on its lead pipeline drug in patients with glioblastoma. Based on this data, it plans to seek an accelerated nod from the FDA.

Zacks 5 months ago

KZIA
-5.95%
ARQT
From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher

If you’ve read all the warnings and still want to jump into some of the top penny stocks to buy, focus on the key fundamentals. That includes its earnings numbers, business models, product pipelines and what market they’re part of. You’ll also want to pay close attention to volume, especially volume spikes. That’s because volume often precedes price. In addition, you’ll also want to see if the volume is being supported by news. Or you’ll get what we just saw with Zapp Electric (NASDAQ:ZAPP).Inve

InvestorPlace 5 months ago

PLUG

KZIA
-5.95%
Kazia Therapeutics stocks soar following Phase II/III win

Kazia’s stocks jumped by 260% before settling at a still impressive 123% increase on the opening price.

Clinical Trials Arena 5 months ago

KZIA
-5.95%
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma (NCT03522298), a life-threatening brain cancer, where there is an urgent unmet need for new therapeutics.

PR Newswire 5 months ago

KZIA
-5.95%
KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data from its lead program, paxalisib, at the upcoming 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) June 29 – July 2, 2024, in Philadelphia, PA. Kazia concurrently announces publication of an article in European Journal of Cancer highlighting the need for evaluating mutation-specific, CNS penetrant, inhibitors to treat pediatric pati

PR Newswire 6 months ago

KZIA
-5.95%
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

Kazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until November 18, 2024 (the "Second Compliance Period"), to regain compliance with the Minimum Bid Price Requirement.

PR Newswire 7 months ago

KZIA
-5.95%
Kazia concludes first stage of Phase I advanced cancer treatment trial

EVT801 was found to be well-tolerated across all tested doses in the study.

Clinical Trials Arena 8 months ago

KZIA
-5.95%
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objectives of stage 1 of the trial have successfully been met.

PR Newswire 8 months ago

KZIA
-5.95%

Performance Overview

Return	KZIA	DAX P
YTD	-49.03%	+1.54%
1-Year	-54.86%	+21.13%
3-Year	-98.07%	+26.76%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kazia Therapeutics Limited (KZIA)

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

7 Top Stocks Under $10: July 2024 Edition

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?

Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher

Kazia Therapeutics stocks soar following Phase II/III win

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

Kazia concludes first stage of Phase I advanced cancer treatment trial

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

Performance Overview